Academic Journals Database
Disseminating quality controlled scientific knowledge

The clinical utility of gene testing for Alzheimer’s disease

ADD TO MY LIST
 
Author(s): Emily R. Atkins | Peter K. Panegyres

Journal: Neurology International
ISSN 2035-8385

Volume: 3;
Issue: 1;
Start page: e1;
Date: 2011;
Original page

Keywords: Neurology | Alzheimer's disease | gene testing

ABSTRACT
Alzheimer’s disease (AD) is the largest cause of dementia, affecting 35.6 million people in 2010. Amyloid precursor protein, presenilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) ε4 is a susceptibility gene for late-onset AD. The genes for phosphatidylinositol- binding clathrin assembly protein, clusterin and complement receptor 1 have recently been described by genome-wide association studies as potential risk factors for lateonset AD. Also, a genome association study using single neucleotide polymorphisms has identified an association of neuronal sortilin related receptor and late-onset AD. Gene testing, and also predictive gene testing, may be of benefit in suspected familial early-onset AD however it adds little to the diagnosis of lateonset AD and does not alter the treatment. We do not recommend APOE ε4 genotyping.

Tango Jona
Tangokurs Rapperswil-Jona

     Affiliate Program